Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vestra

Executive Summary

P&U receives second "approvable" letter for the reboxetine antidepressant Feb. 23. P&U said it conducted two U.S. trials for Vestra to supplement the non-U.S. data in its NDA following the first "approvable" letter in July, but only one showed efficacy on the primary endpoint (1"The Pink Sheet" Feb. 14, p. 29)

You may also be interested in...



Pharmacia Vestra

Janssen and Pharmacia terminate co-promotion agreement for anti-depressant Vestra (reboxetine). The norepinephrine reuptake inhibitor has been pending since April 1998, and was been deemed "approvable" in July 1999 and again in February 2000 (1"The Pink Sheet" Feb. 28, In Brief). Pharmacia says an additional Vestra clinical study intended to support approval is nearing completion

Pharmacia Vestra

Janssen and Pharmacia terminate co-promotion agreement for anti-depressant Vestra (reboxetine). The norepinephrine reuptake inhibitor has been pending since April 1998, and was been deemed "approvable" in July 1999 and again in February 2000 (1"The Pink Sheet" Feb. 28, In Brief). Pharmacia says an additional Vestra clinical study intended to support approval is nearing completion

Detrol Sales Potential Could Be $1 Bil. With Once-Daily Indication, P&U Says

The sales potential of Pharmacia & Upjohn's overactive bladder treatment Detrol (tolterodine) could be up to half a billion dollars greater than previous projections, pending approval of a once-daily formulation.

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel